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Evaluation of statin users, people with hypercholesterolemia, and
cardiovascular disease patients in the Japan Medical Data Center
claims database
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1Simulstat, Inc., San Diego, United States of America; 2Amgen Astellas Bio-
Pharma K. K., Tokyo, Japan; 3Amgen, Inc., Thousand Oaks, United States of
America; 4National Center for Geriatrics and Gerontology, Obu, Japan
Background: Cardiovascular (CV) disease remains a significant public health
concern in the Japanese population. Evidence from clinical practice (real-world
evidence) describing treatment patterns in patients with CV disease can help
identify gaps and guide efforts to improve patient outcomes.
Purpose: To describe statin use and low density lipoprotein cholesterol (LDL-C)
levels across three cohorts in Japan.
Methods: We conducted a retrospective cohort study of three adult (≥18 years)
patient groups in the JMDC medical and pharmacy claims database: (1) patients
with diagnosed hypercholesterolemia, (2) patients with a recent myocardial in-
farction (MI) or stroke, and (3) statin users. The first date a patient met the in-
clusion criteria for any of the cohorts in 2014 was assigned as the index date;
cohorts were not mutually exclusive. We used one-year baseline and follow-up
periods. Statin use was defined as having at 1+ prescription with ≥14 days’ sup-
ply during baseline. Statin intensity dosage categories were adapted from the
U.S. AHA/ACC 2013 Guidelines as maximum tolerated, greater than moderate,
moderate, and low intensity. The highest dose was used if multiple prescription
claims were found.
Results: We identified 51,226 patients with diagnosed hypercholesterolemia,
10,673 patients with an MI/stroke, and 59,399 statin users. The majority were
male (62% hypercholesterolemia 68% MI/stroke, and 63% statin users, respec-
tively), and the average ages were 54, 58, and 56 years, respectively. Statin
use was less prevalent in the MI/stroke cohort (47%) than among hypercholes-
terolemia patients (72%), with only 3% of patients taking statin and ezetimibe con-
comitantly (all cohorts). Overall, moderate intensity statin use was most prevalent.
Use of maximally tolerated statin dose was very low (1–2%). When considered
within ACC/AHA guideline definition, many (55–62%) would be categorized as
taking low intensity statins and <1% of all patients would be considered as taking
high intensity or maximally tolerated statins.
Among patients with an LDL-C lab value during baseline (53–64%), 79%, 68%,
77% had LDL-C levels ≥100 mg/dL (2.6 mmol/L), respectively. In all cohorts, LDL-
C levels were lower among patients receiving higher intensity statin dose. Among
the small number of patients taking concomitant statin+ezetimibe, fewer patients
had LDL ≥100mg/dL (43–62%).
Conclusions: Japanese guidelines recommend treating patients with lipid-
lowering medications to LDL-C levels <100 mg/dL but in clinical practice fewer
than 50% of patients achieve that, identifying an area for potential improvement.
Future research will describe rates of cardiovascular events in these real-world
Japanese patient populations.
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additional funding was provided.
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Efficacy and safety of switching simvastatin intolerant patients with
coronary artery disease to rosuvastatin treatment
A.B. Shek, R.D. Kurbanov, G.J. Abdullaeva, A.V. Nagay, S.U. Hoshimov,
U.I. Nizamov. Specialized Cardiology Center of the Republic of Uzbekistan,
Tashkent, Uzbekistan
Objective: To study genetic determinants of simvastatin intolerance in ethnic
Uzbek patients with coronary artery disease (CAD) and the efficacy and safety of
their switching to treatment with rosuvastatin.
Material and methods: The prospective case-control research included 50 pa-
tients with CAD, who demonstrated statin-induced adverse liver effects (transami-
nase level increases 3 times and more – in 37 cases) or statin-induced elevations
in serum CK (of >3×UNL – in 13 cases) at treatment with simvastatin with the
dose of 10–20 mg/day for 3 months of treatment. Control group contained 50 pa-
tients treated with simvastatin with the dose of 20–40 mg/day for one year with-
out side effects. Patients were genotyped for polymorphisms in the genes cod-
ing for the cytochrome P450 (CYP) metabolic enzymes: CYP3A5 (6986A>G),
CYP2C9 (430C>T), CYP2C9 (1075A>C), and hepatic influx and efflux trans-
porters SLCO1B1 (521T>C) and BCRP (ABCG2, 421C>A) by means of PCR-
RFLP method.
Results: Among patients with simvastatin intolerance, compared to the control
group, the following genotypes were observed more frequently with high level of
confidence: CYP3A5 *3/*3, compared to genotype variants *1/*3 and *1/*1 (OR
9.33; 95% CI 3.37–25.9; P=0.0001) and BCRP CA (OR 3.22; 95% CI 1.25–8.30;
P=0.024) compared to the AA genotype variant. When 37 patients with side liver
effects from simvastatin treatment were compared with the control group the *3/*3
genotype of the CYP3A5 gene (P=0.0001) and variant genotype of the CA BCRP
gene (p=0.0001) were also observed more frequently. However, when the 13 pa-
tients who had side muscle symptoms were compared with the control group
(n=50), it was found that in the “case” group the genotype group 3*/3* CYP3A5
gene (OR 8.6; 95% CI 2.1–34.1; P=0.003) and C allele carriers of the gene poly-
morphism SLCO1B1 (OR 7.2; 95% CI 1.7–13.6; P=0.005) were predominant.
When the 50 patients of the “case” group were switched to the starting dose of
rosuvastatin 5 mg, intolerance symptoms were observed in 29 (58%) against 21.
In this case study, the groups differed significantly only at the prevalence of the
*3/*3 genotype CYP3A5 (OR 5.25; 95% CI 1.6–17.8; P=0.014): *3/*3 genotype
CYP3A5 was observed in 21 of 29 (72.4%) patients of the first group, and only
in 7 of 21 (33.4%) in the second group. Moreover, 8 (61.5%) of 13 patients with
muscle and 21 (56.8%) of 37 patients with the hepatic side effects of the sim-
vastatin, tolerated 5 mg dose of rosuvastatin, respectively. This may indicate the
presence of other metabolic pathways of the hydrophilic rosuvastatin in liver un-
like the lipophilic simvastatin.
Conclusion: In 58% of ethnic Uzbek patients with the CAD with the simvas-
tatin intolerance symptoms, serious side effects at switching to a starting dose
of the rosuvastatin were not observed and it should be noted that in most cases
(72.4%) this phenomenon was observed among the carriers of *3/*3 genotype of
the CYP3A5 (6986A> G) gene.
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Introduction: The electroanatomical mapping of idiopathic ventricular tach-
yarrhythmias (iVT) - premature ventricular contractions (PVC) and idiopathic ven-
tricular tachycardia (VT) - is dependent on the recording of spontaneous PVC or
induction of the clinical VT during the procedure to obtain the iVT activation map.
The presence of infrequent and non-inducible iVT may preclude ablation. Pace-
matching (PM) mapping of the anatomical region on interest, using the PaSo™
algorithm, may allow to circumvent this limitation.
Purpose: Determination of the utility of the PaSo™pace-matching mapping for
iVT ablation
Methods: A single-center retrospective study was made, with inclusion of con-
secutive patients undergoing iVT ablation between October 2013 and October
2016. It was collected electroanatomical data, including the highest correlation
obtained by PM (PaSo™). Success of the procedure was assessed (defined as
the elimination of spontaneous PVC during the electrophysiological study and
non-inducible iVT at the end) and the ability of the PaSo™ pace-matching map-
ping to guide effective ablation was determined.
Results: 29 patients were studied (62.1% women, mean age 52.8±14.7 years).
65.5% presented symptomatic frequent PVC and 34.5% VT. The most frequent
anatomic origin was the right ventricular outflow tract (58.6%), followed by the
left coronary cusp (20.7%), mitro-aortic continuity (13.8%) and papillary muscles
(6.9%). The ablation was successful (PVC elimination during the procedure) in
75.9% of the cases. In 79.3% of the cases it was possible to obtain an activation
map; in 20.7% (6 cases) it was only possible to obtain a pace-matching map,
because ocurred suppression of PVC during the procedure, and success was
achieved in 5 of these cases. There was no relationship between success and
anatomical region of origin of the iVT. The mean value of the better pace-matching
correlation was 94.45% ± 3.95%, being significantly higher when the zone of in-
terest was located in the right ventricle (95.71±3.23 vs. 92.68±4.3, p=0.04). There
was a positive and significant association between the PaSo™ correlation value
and success (r=0.554; p=0.007). Significantly higher correlations were observed
in successful ablations [95.9% vs 92%; p=0.006), and the PaSo™ correlation
value was a good predictor of success (AUC: 0.874, 95% CI 0.74–1.0, p=0.003).
The pace-matching threshold of 93.55% predicted ablation success with 86.4%
sensitivity and 85.7% specificity.
Conclusion: In patients with iVT, pace-matching mapping provides a suitable
method for performing ablation procedure, and it is essential in patients where
spontaneous suppression of PVC occurs during the procedure. The achievement
of a pace-matching correlation>93.55% conveniently identifies the dysrhythmic
focus, allowing increasing of ablation success.
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X-ray exposure in cardiac electrophysiology. a retrospective analysis
over 6 years of activity in a modern, large volume laboratory
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G. Lumia1, G. Vettor1, C. Vignati1, M. Moltrasio1, F. Tundo1, G.M. Fassini1,
C. Carbucicchio1, A. Natale2, C. Tondo1. 1Cardiology Center Monzino IRCCS,
Cardiology Center Monzino IRCCS, Milan, Italy; 2Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center, Austin, United States of America
Background: Only few studies have systematically evaluated electrophysiologi-
cal (EP) fluoroscopy data. Diagnostic reference levels (DRLs) for EP and device
implantation (DI) procedures have not yet been proposed.
Purpose: Aims of this study were: to quantify ionizing radiation exposure for
EP/DI procedures in a very large series of patients; to analyze the X-ray expo-
sure trend over years; and to analyze radiation exposure in patients undergoing
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